Secukinumab biosimilars are in development, and their market entry hinges on patent expirations and regulatory approvals. As of the latest information, several companies are actively working on secukinumab biosimilars, aiming to offer more affordable treatment options for conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].
When do Secukinumab patents expire?
The patent landscape for secukinumab is complex, with multiple patents covering various aspects of the drug, including its composition, method of use, and manufacturing processes. DrugPatentWatch.com tracks these patents and their expiry dates. Generally, primary patents for many blockbuster drugs begin to expire in the mid-to-late 2020s, opening doors for biosimilar competition. However, secondary patents, which can extend market exclusivity, may expire later [2]. The exact expiry dates for secukinumab's key patents will determine when biosimilar manufacturers can launch their products without infringing on existing intellectual property.
What are the challenges in developing Secukinumab biosimilars?
Developing a biosimilar involves demonstrating high similarity to the reference biologic in terms of analytical, clinical, and non-clinical attributes. For secukinumab, this means proving that the biosimilar has no clinically meaningful differences in terms of safety, purity, and potency. The complexity of large molecule biologics like secukinumab presents significant analytical challenges in demonstrating this similarity. Manufacturing consistency and scale-up are also critical hurdles [1].
How do Secukinumab biosimilars compare to the original drug?
Biosimilars are highly similar to the reference biologic and are approved for all the same indications. They are not exact copies but are approved based on extensive analytical, preclinical, and clinical data showing no significant differences in safety, efficacy, and immunogenicity compared to the reference product. Patients can expect similar treatment outcomes with a secukinumab biosimilar as they would with the originator drug [1].
Who is developing Secukinumab biosimilars?
Several pharmaceutical companies, including both established biosimilar manufacturers and innovator companies seeking to enter the biosimilar space, are engaged in the development of secukinumab biosimilars. Some of these include Amgen, Samsung Bioepis, and Sandoz, among others [1].
What are the potential benefits of Secukinumab biosimilars?
The primary benefit of secukinumab biosimilars is increased market competition, which is expected to lead to lower prices. This could improve patient access to effective treatments for inflammatory conditions, reduce healthcare costs, and provide more treatment options for physicians [1].
What is the regulatory pathway for Secukinumab biosimilars?
In the United States, biosimilars are approved by the Food and Drug Administration (FDA) under the Biologics Price Competition and Innovation Act (BPCIA). In Europe, the European Medicines Agency (EMA) is responsible for their approval. The regulatory process requires manufacturers to submit extensive data demonstrating biosimilarity to the reference product [1].
What are the implications for patients with psoriatic arthritis and psoriasis?
For patients with psoriatic arthritis and psoriasis, the availability of secukinumab biosimilars could mean more affordable access to treatments that effectively manage their conditions. This increased access may lead to better disease control, improved quality of life, and reduced financial burden for patients and healthcare systems [1].
Can biosimilars be prescribed interchangeably with Secukinumab?
Interchangeability means a biosimilar can be substituted for the reference biologic by a pharmacist without the intervention of the prescriber. While a biosimilar designation does not automatically confer interchangeability, companies can conduct additional studies to demonstrate this. Once approved as interchangeable, a secukinumab biosimilar could be substituted for the originator product, further enhancing access and potentially driving down costs [1].
Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com